

2025 Summit and Summit KOL EASL Abstracts

Summit Contributor	ID	Title
Mazen Noureddin	Poster WED-468	Non-invasive markers to predict biopsy response in people with metabolic dysfunction-associated steatohepatitis and fibrosis: exploratory analysis of a phase 2 trial of glucagon receptor/glucagon-like peptide-1 receptor dual agonist, survodutide
Mazen Noureddin	Presentation SAT-445	Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis
Mazen Noureddin	General Session GS-012	Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)
Mazen Noureddin	Presentation OS-098	Direct effects of survodutide on liver endpoints beyond weight loss: insights from a phase 2 trial of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis
Mazen Noureddin	Symposia	Is liver biopsy still required in clinical trials in MetALD and ALD?
Naim Alkhouri	Poster SAT-438	General characteristics of the patients prescribed Resmetirom: data derived from six tertiary care centers in the United States
Naim Alkhouri	Presentation LBO-002	Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis